Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) (PROVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03090880
Recruitment Status : Not yet recruiting
First Posted : March 27, 2017
Last Update Posted : March 27, 2017
Ministry of Health, France
National Cancer Institute, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Prospective randomized open multicenter trial with blinded adjudication of endpoints to assess the efficacy of six-month low-dose LMWH for the prevention of symptomatic or incidental VTE in patients with stage IV lung cancer and elevated D-dimer.

Condition or disease Intervention/treatment Phase
Venous Thromboembolism Lung Neoplasm Drug: Tinzaparin Sodium Phase 3

Detailed Description:
Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place in outpatient clinic at day 90, day 180 and day 360. Blood sampling for biomarkers will be performed at inclusion visit and day 90.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Long-term Prophylaxis of Venous Thromboembolism With Low-molecular-weight Heparin in Patients With Metastatic Lung Cancer
Estimated Study Start Date : April 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Control
usual care,
Experimental: Experimental
tinzaparin sodium
Drug: Tinzaparin Sodium
Subcutaneous tinzaparin 4,500 IU once daily for six months.

Primary Outcome Measures :
  1. venous thromboembolic events [ Time Frame: 6 months ]

    all VTE events during the six-month treatment period including:

    • objectively confirmed symptomatic pulmonary embolism (PE),
    • objectively confirmed symptomatic lower-limb deep vein thrombosis (DVT) (including iliac and caval thrombosis),
    • objectively confirmed symptomatic upper extremity DVT,
    • objectively confirmed incidentally diagnosed PE or proximal DVT
    • death due to PE.

Secondary Outcome Measures :
  1. Symptomatic VTE events [ Time Frame: 6 months ]
    Objectively confirmed symptomatic VTE and death due to PE

  2. Venous thromboembolic events [ Time Frame: 12 months ]
    Objectively confirmed symptomatic or incidental VTE during the 12-months study period

  3. Major bleedings [ Time Frame: 6 months ]
    Major bleeding according to the ISTH criteria

  4. Death [ Time Frame: 6 months ]
    Overall mortality and causes of death

  5. Death [ Time Frame: 12 months ]
    Overall mortality and causes of death

Other Outcome Measures:
  1. Risk factors for venous thromboembolism [ Time Frame: 12 months ]
    Risk fators for venous thromboembolism

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18 years
  • Social security affiliation
  • Written informed consent
  • Histologically confirmed stage IV (M1a or M1b) non-small-cell lung cancer, including recurrent non-small-cell lung cancer after a period of complete remission
  • D-dimer > 1,500 µg/L
  • Planned or ongoing chemotherapy or targeted anticancer therapy
  • ECOG 0-2
  • Life expectancy >3 months

Exclusion Criteria:

  • Hypersensitivity to heparin
  • History of heparin-induced thrombocytopenia
  • Ongoing anticoagulant treatment
  • VTE at inclusion
  • Creatinin clearance <30 mL/min
  • Active bleeding
  • Platelet count < 100,000 G/L at inclusion
  • Severe hepatic insufficiency
  • Cancer treated exclusively with supportive care
  • Previous inclusion in the trial
  • Aspirin at daily dosage > 160 mg
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03090880

Contact: Guy Meyer, MD +33 156 093 461

Hôpital Pontchaillou
Rennes, Bretagne, France, 35033
Centre Hospitalier régional d'Orléans
Orléans, Centre, France, 45000
Centre Oscar Lambert
Lille, Hauts de France, France, 59020
Hôpital Avicenne, Hôpitaux universitaires Paris Seine-
Bobigny, Ile de France, France, 93000
Hôpital d'Instruction des Armées Percy
Clamart, Ile de France, France, 92140
Hôpital Louis Mourier
Colombes, Ile de France, France, 92700
Centre Hospitalier Intercommunal de Créteil
Créteil, Ile de France, France, 94000
Centre Hospitalier de Versailles André Mignot
Le Chesnay, Ile de France, France, 78157
Hôpital Bicêtre
Le Kremlin Bicêtre, Ile de France, France, 94275
Institut Curie
Paris, Ile de France, France, 75005
Hôpital Pitié Salpétrière
Paris, Ile de France, France, 75013
Centre Hospitalier Paris Saint-Joseph
Paris, Ile de France, France, 75014
Institut Mutualiste Montsouris
Paris, Ile de France, France, 75014
Hôpital Européen Georges Pompidou
Paris, Ile de France, France, 75015
Hôpital Bichat Claude Bernard
Paris, Ile de France, France, 75018
Hôpital Tenon
Paris, Ile de France, France, 75020
Centre cardiologique du Nord
Saint Denis, Ile de France, France, 93200
Hôpital Foch
Suresnes, Ile de France, France, 92150
Gustave Roussy
Villejuif, Ile de France, France, 94805
Hôpital Larrey
Toulouse, Languedoc-Roussillon-Midi-Pyrénées, France, 31059
CHU de Caen
Caen, Normandie, France, 14033
CHU Poitiers
Poitiers, Nouvelle-Aquitaine, France, 86000
Institut de cancérologie de l'Ouest
Saint Herblain, Pays de la Loire, France, 44805
Centre Hospitalier Annecy Genevois
Annecy, Rhône Alpes, France, 74374
Groupement Hospitalier Est Hospices civils de Lyon
Lyon, Rhônes Alpes, France, 69000
Institut de Cancérologie Lucien Neuwirth
Saint Priest, Rhônes-Alpes, France, 42270
CHU de Rouen, Hôpital Charles Nicolle
Rouen, Seine Maritime, France, 76000
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France
National Cancer Institute, France
Principal Investigator: Guy Meyer, MD Assistance Publique - Hôpitaux de Paris

Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT03090880     History of Changes
Other Study ID Numbers: P150963
2016-002546-23 ( EudraCT Number )
PHRC ( Other Grant/Funding Number: 15-059 )
First Posted: March 27, 2017    Key Record Dates
Last Update Posted: March 27, 2017
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Low-molecular-weight Heparin

Additional relevant MeSH terms:
Venous Thromboembolism
Lung Neoplasms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Heparin, Low-Molecular-Weight
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action